Targeting moaA1 gene is a potential target for multi-drug resistance in Mycobacterium tuberculosis.

Rohini Kumari, Pramod katara

Abstract


The conventional drug treatments of Mycobacterium tuberculosis result in more drug resistance. Identification of the new target molecules can drive novel therapeutic agents to overcome multi-drug resistance. Computational analysis can accelerate the major research for the identification of potential therapeutic targets and drugs. Therefore, we performed the gene expression analysis and single nucleotide polymorphism (SNP) of potential genes from multiple drug-treated patients such as capreomycin (CAP), isoniazid (INH) and rifampicin (RIF) (GEO-GSE53843). The DEGs data revealed that about 11 genes are commonly dysregulated by above conventional drug treatments. While 37 genes are INH-specific treatment dysregulated. Pathway analysis revealed that these dysregulated genes have an essential role in the drug metabolic process and influx mechanism. Further, overall genomics analysis suggested that the moaA1 gene could serve as a potential target inhibitor of M.tuberculosis. The moaA1 gene is over expressed in multiple drug resistance patients. It is known as a catalyzes the cyclization of GTP to (8s)-3’-8-cyclo-7,8-dihydroguanosine 5’-triphosphate which play important role in the molybdopterin biosynthesis.

Full Text:

KUMARI ET AL 2022

Refbacks

  • There are currently no refbacks.


Published by:

Indian Science and Technology Foundation (ISTF)

 C-1/31, Yamuna Vihar, New Delhi-110053 

www.isto-india.org

Email: contact@isto-india.org